← Leaderboards
Manuel Litchman
Mustang Bio, Inc.
$1,998,672
Attributed
$1,998,672
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $999.3K · FY2021–22$1M$750K$500K$250K$0
'21
'22
Funding mix
By agency
NIH$1,998,672 · 1
By mechanism
R44$1,998,672 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Antigens”
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$42,191,190
- Bala Raja · Luminostics, Inc.$28,624,460
- Hanjoon Ryu$28,519,898
- Thomas Denny · Duke University$22,999,550
- Jay Evans · University Of Montana$22,565,626
- Julie Ake · National Institute Of Allergy And Infectious Diseases$22,000,000
Research focus
AntigensAutologousBaseB-Cell LymphomasB-Cell Nonhodgkins LymphomaBindingBloodB-LymphocytesB Lymphoid MalignancyBone MarrowCar T Cell TherapyCd19 GeneCd28 GeneCd4 Positive T LymphocytesCd8-Positive T-LymphocytesCell TherapyCellular EngineeringCellular ImmunotherapyCellular TransductionChimeric Antigen ReceptorChimeric Antigen Receptor T CellsChronicChronic Lymphocytic LeukemiaAnti-Cd20
Grant awards (2)
A Phase 1, Open Label, Multicenter Trial to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory CD20+ B-Cell NHL or CLL$999,336
R44 · FY2022 · CA · contact PI
A Phase 1, Open Label, Multicenter Trial to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory CD20+ B-Cell NHL or CLL$999,336
R44 · FY2021 · CA · contact PI